Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor - Full Text View

Sponsor:	Niigata University Medical and Dental Hospital
Information provided by:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00769782

Purpose

RATIONALE: Surgery may be an effective treatment for liver metastasis from a gastrointestinal stromal tumor.

PURPOSE: This phase II trial is studying how well surgery works in treating patients with liver metastasis from a gastrointestinal stromal tumor.

Condition	Intervention	Phase
Gastrointestinal Stromal Tumor Metastatic Cancer	Procedure: therapeutic conventional surgery	Phase II

Study Type:	Interventional
Study Design:	Masking: Open Label Primary Purpose: Treatment
Official Title:	Phase II Multicenter Clinical Trial on Surgery for Patients With Resectable Hepatic Metastasis From Gastrointestinal Stromal Tumors (GISTs)

Resource links provided by NLM:

Genetics Home Reference related topics: gastrointestinal stromal tumor

MedlinePlus related topics: Cancer

U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:

Recurrence-free survival [ Designated as safety issue: No ]

Secondary Outcome Measures:

Overall survival [ Designated as safety issue: No ]
Microscopically complete resection rate (R0 resection) [ Designated as safety issue: No ]
Postoperative morbidity and mortality [ Designated as safety issue: No ]

Estimated Enrollment:	44
Study Start Date:	October 2008
Estimated Primary Completion Date:	September 2014 (Final data collection date for primary outcome measure)

Detailed Description:

OBJECTIVES:

To evaluate the safety and efficacy of surgery in patients with resectable hepatic metastasis secondary to gastrointestinal stromal tumor.

OUTLINE: This is a multicenter study.

Patients undergo surgical resection of hepatic metastasis.

Eligibility

Ages Eligible for Study:	20 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Diagnosis of gastrointestinal stromal tumor (GIST)
Hepatic metastasis meeting the following criteria:
- Clinically diagnosed as surgically resectable with no macroscopic residual tumor
- No more than 3 hepatic metastases
- Synchronous hepatic metastasis allowed provided primary tumor is also resectable
- Does not require radiofrequency ablation and/or microwave coagulation therapy to control the disease
No extrahepatic metastasis
No history of GIST recurrence

PATIENT CHARACTERISTICS:

ECOG performance status 0-1
Leukocyte count ≥ 3,000/μL
Neutrophil count ≥ 1,500/μL
Hemoglobin ≥ 8.0 g/dL
Platelet count ≥ 75,000/μL
Total bilirubin ≤ 2.0 mg/dL
ALT and AST < 120 IU/L
GTP < 210 IU/L
Not pregnant
No poorly controlled diabetes mellitus
No NYHA class III-IV cardiac function
No hepatitis B or hepatitis B carriers
No other malignancy requiring treatment

PRIOR CONCURRENT THERAPY:

See Disease Characteristics
No prior interventional radiology for metastatic disease
No prior or concurrent imatinib mesylate
No other concurrent treatment

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00769782

Locations

Japan
Aichi Medical University
Nagoya, Aichi, Japan, 480-1195
Aichi Cancer Center
Nagoya, Aichi, Japan, 464-8681
Hirosaki University, School of Medicine
Hirosaki, Aomori, Japan, 036-8562
National Hospital Organization Kure Medical Center
Kure, Hiroshima, Japan, 737-0023
Hokkaido University Hospital
Sapporo, Hokkaido, Japan, 060-8648
Iwate Medical University Hospital
Morioka, Iwate, Japan, 020-8505
Kanagawa Cancer Center
Yokohama, Kanagawa, Japan, 241-0815
International Goodwill Hospital
Yokohama, Kanagawa, Japan, 245-0006
Kochi Medical School
Nankoku, Kochi, Japan, 783-8505
Kyoto Second Red Cross Hospital
Kanigyou-ku, Kyoto, Japan, 602-8026
University of Miyazaki Hospital
Kiyotake, Miyazaki, Japan, 889-1692
Niigata Prefectural Central Hospital
Joetsu, Niigata, Japan, 943-0192
Nagaoka Chuo General Hospital
Nagaoka, Niigata, Japan, 940-8653
Kawasaki Medical School
Kurashiki, Okayama, Japan, 701-01
Ryukyu University Hospital
Nishiharacho, Okinawa, Japan, 903-0215
Sakai Municipal Hospital
Sakai, Osaka, Japan, 590-0064
Osaka University Hospital
Suita, Osaka, Japan, 565-0871
Toyonaka Municipal Hospital
Toyonaka, Osaka, Japan, 560-8565
Saitama Medical University International Medical Center
Hidaka, Saitama, Japan, 350-1241
Hamamatsu University School of Medicine
Hamamatsu, Shizuoka, Japan, 431-3192
University of Yamanashi Hospital
Chuo, Yamanashi, Japan, 409-3898
Kyushu University Hospital
Fukuoka, Japan, 812-8582
Fukushima Medical University Hospital
Fukushima, Japan, 960-1295
Kagoshima University
Kagoshima, Japan, 890-8520
Kimitsu Chuo Hospital
Kisarazu-city, Japan, 292-8535
Kochi Health Sciences Center
Kochi, Japan, 781-8555
Kumamoto University Hospital
Kumamoto, Japan, 860-8556
Niigata University Medical and Dental Hospital
Niigata, Japan, 951-8510
Niigata Cancer Center Hospital
Niigata, Japan, 951-8566
Okayama University Hospital
Okayama, Japan, 700-8558
Shizuoka Cancer Center
Shizuoka, Japan, 411-8777
Juntendo University Shizuoka Hospital
Shizuoka, Japan, 410-2295
Tokushima University Hospital
Tokushima, Japan, 770-8503
Tokyo Metropolitan - Komagome Hospital
Tokyo, Japan, 113-0021
Keio University Hospital
Tokyo, Japan, 160-8582
Toyama University Hospital
Toyama, Japan, 930-0194
Yamagata University Hospital
Yamagata, Japan, 990-9585

Sponsors and Collaborators

Niigata University Medical and Dental Hospital

Investigators

Principal Investigator:

Tatsuo Kanda, MD

Niigata University Medical and Dental Hospital

More Information

Additional Information:

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

No publications provided

ClinicalTrials.gov Identifier:	NCT00769782 History of Changes
Other Study ID Numbers:	CDR0000615624, NIIGATAU-TRIGIST0804
Study First Received:	October 8, 2008
Last Updated:	August 31, 2011
Health Authority:	United States: Federal Government

Keywords provided by National Cancer Institute (NCI):

gastrointestinal stromal tumor
liver metastases

Additional relevant MeSH terms:

Neoplasm Metastasis
Neoplasms
Neoplasms, Second Primary
Gastrointestinal Stromal Tumors
Neoplastic Processes
Pathologic Processes

Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases

ClinicalTrials.gov processed this record on February 09, 2012